ENGOT-en9/LEAP-001: A phase III, randomized, active-controlled, open-label study of pembrolizumab plus lenvatinib versus paclitaxel plus carboplatin for newly diagnosed advanced or recurrent endometrial cancer
Tarih
2020Yazar
Marth, C.
Vulsteke, C.
Rubio, M. J. R.
Makker, V.
Braicu, E. I.
McNeish, I. A.
Madry, R.
Ayhan, A.
Hasegawa, K.
Wu, X.
Dutta, L.
Xu, C.
Keefe, S.
Lee, J.
Pignata, S.